Search

Changes to Formulary as of 12th September 2022:

BNF Category Number

Product/indication

Detail of change

6.1.2.3

Setmelanotide

Added as a RED drug and added link to NICE HST21

8.1.5

Duvelisib

Added link to NICE TA811

8.1.5

Abemaciclib

Added link to NICE TA810

8.2.2

Imlifidase

Added as a RED drug and added link to NICE TA809

4.8

Fenfluramine

Added as a RED drug and added link to NICE TA808

9.1.3

Roxadustat

Added as a RED drug and added link to NICE TA807

10.1.3

Belimumab

Added as a NOT APPROVED drug for this indication and added link to NICE TA806

2.12

Icosapent ethyl

Added as a GREEN drug and added link to NICE TA805

10.1.3

Risankizumab

Added as a RED drug and added link to NICE TA803

1.4.2

Teduglutide

Added as a RED drug and added link to NICE TA804

8.1.5

Cemiplimab

Added as a RED drug and added link to NICE TA802

8.1.5

Pembrolizumab

Added link to NICE TA801

11.8.2.3

Faricimab

Added as RED drug and added link to NICE TA790 and NICE TA800

8.1.5

Durvalumab

Added link to NICE TA798

8.1.5

Efortumab vedotin

Added as NOT APPROVED drug for this indication and added link to NICE TA797

8.1.5

Venetoclax

Added link to NICE TA796

8.1.5

Ibrutinib

Added as a NOT APPROVED drug for this indication and added link to NICE TA795

8.2.4

Diroximel fumarate

Added as a RED drug and added link to NICE TA794

10.1.3

Anifrolumab

Added as a NOT APPROVED drug and added link to NICE TA793

1.5.3

Filgotinib

Added as a RED drug and added link to NICE TA792

3.2

Flutiform MDI and Khaler

Removed from formulary

3.2

Trimbow 127/5/9 inhaler

Added as a GREEN drug

6.2.1

Liothyronine Capsules

Updated wording to match Grey List  and not that GPs may continue therapy after 3 month trial by specialist

5.1.7

Fosfomycin sachets

Changed from AMBER Specialist Initiation drug to Green (second line)

5.1.7

Fidaxomicin 40mg/ml oral suspension

Added as a AMBER Specialist Initiation drug

2.2.1

Metolazone

Changed from RED to AMBER Specialist Initiation drug

4.7.2

Dihydrocodeine

Added exception to RED status that may be prescribed on advice of pain team

13.6.3

Ivermectin 1% cream

Change to a first line treatment option

4.7.2

Fentanyl 100microgram in 2ml via intranasal route

Added as a RED drug

3.1.1

Nebulised asthma rescue therapy in children: home use of nebulisers in paediatric asthma should be initiated and managed only by specialists

Added link to MHRA Drug Safety Update

4.8

Topiramate (Topamax): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure

Added link to MHRA Drug Safety Update

6.1.2.2

Metformin and reduced vitamin B12 levels: new advice for monitoring patients at risk

Added link to MHRA Drug Safety Update

Changes to Formulary as of 18th July 2022:

BNF Category Number

Product/indication

Detail of change

6.6.2.2

Denosumab Xgeva®

Added as a RED drug

6.4.2.1

Testim® and Tostran® 2%

 

Testim(R) gel and Tostran(R) 2%  gel - also approved as GREEN drugs for the treatment of low sexual desire in menopausal women as a second line option after HRT in line with NICE guidance.

6.1.2.3

Lixisenatide

Removed 10microgram strength as discontinued

6.1.2.2

Metformin sachets

Added as alternative to oral liquid

1.5.2

Budesonide orodispersible (Jorveza®)

Added as an AMBER Specialist Initiation drug for maintenance treatment

4.7.3 and 4.8.1

Pregabalin (Lyrica): findings of safety study on risks during pregnancy

 

Added link to MHRA Drug Safety Update

6.6.2.2

Denosumab 60mg (Prolia): should not be used in patients under 18 years due to the risk of serious hypercalcaemia

Added link to MHRA Drug Safety Update

5.3.6

Paloxid

Added as a RED drug

8.1.5

Daratumumab

Added link to NICE TA783

8.2.4

Niraparib

Added as RED drug and added link to NICE TA784

8.2.4

Nivolumab

Added as a NOT APPROVED drug for this indication and added link to NICE TA785

8.1.5

Tucatinib

Added as RED drug and added link to NICE TA786

8.1.5

Venetoclax

Added link to NICE TA787

9.8.1

Elosulfase alfa

Added as RED drug and added link to NICE HST19

8.1.5

Avelumab

Added link to NICE TA788

8.1.5

Tepotinib

Added as RED drug and added link to NICE TA789

6.6.2.2

Romosozumab

Added as RED drug and added link to NICE TA789

8.1.5

Selmetinib

Added as RED drug and added link to NICE HST20

Changes to Formulary as of 13th May 2022:

BNF Category Number

Product/indication

Detail of change

6.2.1

Liothyronine Capsules

Added as an AMBER Specialist Initiation drug

2.5.1a

Tadalafil

Added as RED drug for pulmonary hypertension

4.2.1.2

Risperidone oral solution

Added as an AMBER Specialist Initiation drug

7.2.1

Topical estriol

Added off label recurrent UTI indication

7.2.1

Gynest®

Changed to GREEN alternative drug

5.7.2

Dihydrocodeine 30mg tablets

Changed to RED drug for use in breastfeeding only

6.4.1.2

Progesterone 200mg vaginal caps (Urogestan®)

Added as an AMBER Specialist Initiation drug for prevention of miscarriage

10.1.3

Hydroxychloroquine, chloroquine: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions

Added link to MHRA Drug Safety Update

3.7

Ivacaftor, tezacaftor, elexacaftor (Kaftrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on liver function testing

Added link to MHRA Drug Safety Update

8.1.3

Cladribine (Mavenclad): new advice to minimise risk of serious liver injury

Added link to MHRA Drug Safety Update

2.3.2

Amiodarone (Cordarone X): reminder of risks of treatment and need for patient monitoring and supervision

Added link to MHRA Drug Safety Update

6.1.2.2

Metformin in pregnancy: study shows no safety concerns

Added link to MHRA Drug Safety Update

8.1.5

Olaparib

Added as a NOT APPROVED drug for this indication and added link to NICE TA762

8.1.5

Daratumumab

Added link to NICE TA763

4.7.4.2

Fremanezumab

Added link to NICE TA764

8.1.5

Venetoclax

Added link to NICE TA765

8.1.5

Pembrolizumab

Added link to NICE TA766, NICE TA770, and NICE TA772

8.2.4

Ponesimod

Added as RED drug and added link to NICE TA767

10.1.3

Upadacitinib

Added link to NICE TA768

8.1.5

Daratumumab

Added as a NOT APPROVED drug for this indication and added link to NICE TA771

1.9.1

Odevixibat

Added as RED drug and added link to NICE HST17

6.1.2.3

Empagliflozin

Added as a GREEN Specialist Initiation for this indication and added link to NICE TA773

8.2.4

Lenalidomide

Added as a NOT APPROVED drug for this indication and added link to NICE TA774

4.4

Pitolisant

Added as a NOT APPROVED drug for this indication and added link to NICE TA776

4.4

Solrimafetol

Added as a NOT APPROVED drug for this indication and added link to NICE TA777

9.1.3

Pegcetacoplan

Added as RED drug and added link to NICE TA778

8.1.5

Dostarlimab

Added as RED drug and added link to NICE TA779

8.1.5

Nivolumab

Added link to NICE TA780

8.1.5

Sotorasib

Added as RED drug and added link to NICE TA781

8.1.5

Tagraxofusp

Added as a NOT APPROVED drug for this indication and added link to NICE TA782

 

Changes to Formulary as of 11th March 2022:

BNF Category Number

Product/indication

Detail of change

4

Dihydrocodeine oral solution 10mg/5mL

Deleted as no longer available

6.4.2.1

Testosterone 40mg capsules

Deleted as no longer available

13.8

Tirbanibulin (Klisyri®) 10 mg/g ointment

Added as a GREEN drug

1.9.1

Ursodeoxycholic acid 250mg capsules

Added as a GREEN drug

3.2.2

Duoresp Spiromax 160/4.5 inhaler

Added as a GREEN drug for paediatric use in asthma

4.8.1

Zonisamide 100mg/5ml oral suspension

Added as an AMBER Specialist Recommendation drug

1.4.2

Loperamide

Added note about restricting use of orodispersible tablets

2.8.2

Acenocoumarol

Changed to a GREEN drug.

2.8.2

Rivaroxaban for CAD/PAD

To clarify on formulary that is an AMBER Specialist Initiation drug.

3.7

Sodium chloride 7% nebs

To clarify on formulary that is an AMBER Specialist Recommendation drug.

9.6.5

Vitamin E suspension

To clarify on formulary that is an AMBER Specialist Recommendation drug.

1.3.5

Esomeprazole

To clarify on formulary that is an AMBER Specialist Initiation drug.

1.3.5

Omeprazole suspension

To clarify on formulary that is an AMBER Specialist Initiation drug.

1.5.1

Balsalazide

To clarify on formulary that is an AMBER Specialist Recommendation drug.

1.5.2

Budesonide (Enterocort®)

To clarify on formulary that is an AMBER Specialist Recommendation drug.

1.6.2

Leicarbon A Suppositories

To clarify on formulary that is an AMBER Specialist Initiation drug.

1.6.6

Naldemidine for OIC

To clarify on formulary that is an AMBER Specialist Recommendation drug.

1.9.4

Pancrex V Capsules

To clarify on formulary that is an AMBER Specialist Initiation drug.

2.12

Colesevelam

To clarify on formulary that is an AMBER Specialist Initiation drug.

3

Flutter device

To clarify on formulary that is an AMBER Specialist Initiation drug.

4.1.1

Melatonin (neurology)

To clarify on formulary that is an AMBER Specialist Initiation drug.

4.10.1

Chlordiazepoxide

Changed to a RED drug.

4.2.1.2

2nd gen antipsychotics – oral

To clarify on formulary that is an AMBER Specialist Initiation drug.

4.2.3

Carbamazepine for mania

To clarify on formulary that is an AMBER Specialist Initiation drug.

4.2.3

Lamotrigine for mania

To clarify on formulary that is an AMBER Specialist Initiation drug.

4.2.3

Valproic acid in men

To clarify on formulary that is an AMBER Specialist Initiation drug.

4.2.3

Sodium valproate for bipolar in men

To clarify on formulary that is an AMBER Specialist Initiation drug.

4.3.4

Duloxetine for depression/diabetic neuropathy

Changed to a GREEN drug.

4.3.4

Reboxetine

To clarify on formulary that is an AMBER Specialist Initiation drug.

4.7.2

Fentanyl (Abstral®) for palliative care

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.7.2

Methadone (pain in palliative care)

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.7.2

Tapentadol

To clarify on formulary that is an AMBER Specialist Initiation drug.

4.7.3

Lidocaine patches

To clarify on formulary that is an AMBER Specialist Initiation drug.

4.8

Brivarcetam

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.8

Carbmazepine (epilepsy)

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.8

Clobazam

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.8

Clonazepam

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.8

Eslicarbazpine

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.8

Ethosuximide

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.8

Gabapentin

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.8

Lacosamide

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.8

Lamotrigine

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.8

Levetiracetam

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.8

Oxcarbazepine

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.8

Perampanel

To clarify on formulary that is an AMBER Specialist Initiation drug.

4.8

Phenobarbital

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.8

Phenytoin

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.8

Pregabalin

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.8

Piracetam

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.8

Primidone

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.8

Sodium valproate in men (epilepsy)

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.8

Tiagabine

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.8

Topiramate

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.8

Vigabatrin

To clarify on formulary that is an AMBER Specialist Initiation drug.

4.8

Zonisamide

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.9.1

Co-beneldopa

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.9.1

Co-careldopa

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.9.1

Stavelo®, Stravasi®

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.9.1

Pramipexole

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.9.1

Ropinirole

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.9.1

Rotigotine

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.9.1

Selegiline

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.9.1

Rasagiline

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.9.1

Entacapone

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.9.1

Opicapone

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.9.1

Safinamide

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.9.2

Orphenadrine

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.9.2

Procyclidine

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.9.2

Trihexylphenidyl

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.9.3

Tetrabenazine

To clarify on formulary that is an AMBER Specialist Recommendation drug.

4.9.3

Haloperidol for tics

Changed to a GREEN drug.

5.1.9

TB drugs

Changed to RED drugs.

6.1.1

Insulin degludec

To clarify on formulary that is an AMBER Specialist Initiation drug.

6.1.1

Toujeo® insulin

To clarify on formulary that is an AMBER Specialist Initiation drug.

6.1.2.2

Metformin for Polycystic Ovary Syndrome

To clarify on formulary that is an AMBER Specialist Recommendation drug.

6.1.2.3

Linagliptin

Changed to a GREEN drug.

6.3

Hydrocortisone granules (Alkindi®)

To clarify on formulary that is an AMBER Specialist Initiation drug.

6.7

Bromocriptine

To clarify on formulary that AMBER Specialist Initiation (AMBER Specialist Recommendation when used to supress lactation).

6.7

Cabergoline

To clarify on formulary that AMBER Specialist Initiation (AMBER Specialist Recommendation when used to supress lactation).

8.2.4.2

LHRH analogues

To clarify on formulary that is an AMBER Specialist Initiation drug.

8.3.2

Megestrol

To clarify on formulary that is an AMBER Specialist Initiation drug.

8.3.2

Norethisterone (chapter 8)

To clarify on formulary that is an AMBER Specialist Initiation drug.

8.3.2

Medroxyprogesterone (chapter 8)

To clarify on formulary that is an AMBER Specialist Initiation drug.

8.3.4.1

Anastrazole

To clarify on formulary that is an AMBER Specialist Recommendation drug.

8.3.4.1

Exemestane

To clarify on formulary that is an AMBER Specialist Recommendation drug.

8.3.4.1

Letrozole

To clarify on formulary that is an AMBER Specialist Recommendation drug.

8.3.4.1

Tamoxifen

To clarify on formulary that is an AMBER Specialist Recommendation drug.

8.3.4.1

Raloxifene

To clarify on formulary that is AMBER Specialist Recommendation for osteoporosis and AMBER Specialist Initiation for breast cancer.

8.3.4.2

Bicalutamide

To clarify on formulary that is an AMBER Specialist Initiation drug.

8.3.4.2

Flutamide

To clarify on formulary that is an AMBER Specialist Initiation drug.

8.3.4.2

Cyproterone

To clarify on formulary that is an AMBER Specialist Initiation drug.

8.3.4.2

Degarelix

To clarify on formulary that is an AMBER Specialist Initiation drug.

9.2.1.2

St Mark’s Solution

To clarify on formulary that is an AMBER Specialist Recommendation drug.

9.5.1.2

Sodium clodronate (oncology pts)

To clarify on formulary that is an AMBER Specialist Recommendation drug.

9.5.2

Sevelamer (non-dialysis)

To clarify on formulary that is an AMBER Specialist Initiation drug.

9.5.2

Lanthanum (non-dialysis)

To clarify on formulary that is an AMBER Specialist Initiation drug.

9.2.1.1

Patiromer

To clarify on formulary that is an AMBER Specialist Initiation drug.

11.8.1

Hylo-Forte eye drops

To clarify on formulary that is an AMBER Specialist Recommendation drug.

13.5.3

Tacrolimus Ointment

To clarify on formulary that is an AMBER Specialist Initiation drug.

13.5.3

Pimecrolimus Ointment

To clarify on formulary that is an AMBER Specialist Initiation drug.

13.12

Glycopyrrolate 1% cream

To clarify on formulary that is an AMBER Specialist Initiation drug.

1.2.1

Glycopyrronium oral solution (Sialanar®)

To clarify on formulary that is an AMBER Specialist Recommendation drug.

18

Bisacodyl rectal solution

To clarify on formulary that is an AMBER Specialist Initiation drug.

7.4.5

Alprostadil for erectile dysfunction

To clarify on formulary that is an AMBER Specialist Initiation drug.

7.4.5

Invicorp injection for erectile dysfunction

To clarify on formulary that is an AMBER Specialist Initiation drug.

1.7

Diltiazem rectal ointment/cream

To clarify on formulary that is an AMBER Specialist Recommendation drug.

10.1.3

Mexilietine

Added link to NICE TA748

4.5

Liraglutide

Added as a NOT APPROVED drug for this indication  and added link to NICE TA749

8.1.5

Olaparib

Added as a NOT APPROVED drug for this indication and added link to NICE TA750

3.4.2

Duplimuab

Added as a RED drug and added link to NICE TA751

10.1.3

Belimumab

Added link to NICE TA752

4.8

Cenobamate

Added as an AMBER Specialist Initiation drug and added link to NICE TA753

8.1.5

Mogamulizumab

Added as a RED drug and added link to NICE TA754

10.2

Risdiplam

Added as a RED drug and added link to NICE TA755

8.1.5

Fedratinib

Added as a RED drug and added link to NICE TA756

8

 

Added link to NG131

4.2

Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium

Added link to MHRA Drug Safety Update

8.1.5

Venetoclax (Venclyxto▼): updated recommendations on tumour lysis syndrome (TLS)

Added link to MHRA Drug Safety Update

5.3.1

Cabotegravir

Added as a RED drug and added link to NICE TA757

4.4

Solriamfetol

Added link to NICE TA758 and deleted link to NTAG recommendation.

8.1.5

Fostamatinib

Added as a NOT APPROVED drug for this indication and added link to NICE TA759

8.1.5

Selpercatinib

Added as a RED drug and added link to NICE TA760

8.1.5

Osimertinib

Added link to NICE TA761

9.2.1.1

Sodium zirconium

Added as AMBER Specialist Initiation for persistent hyperkalaemia.

11.8.2.3

Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals

Added link to MHRA Drug Safety Update

8.1.5

Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error

 

Added link to MHRA Drug Safety Update

 

Changes to Formulary as of 27th January 2022:

BNF Category Number

Product/indication

Detail of change

6.1.2.3

Dapaglifozin

Removed for use in Type 1 diabetes as license for this indication and NICE TA597 withdrawn

5.3.6

Molnupiravir

Added as a RED drug

5.3.6

Ronapreve

Added as a RED drug

5.3.6

Sotrovimab

Added as a RED drug

7.5.5

Avanafil

Changed from GREEN to NOT APPROVED drug

7.5.5

Vardenafil

Changed from NOT APPROVED to GREEN drug

7.5.5

Tadalafil 5mg Once daily

Changed from  AMBER SI to GREEN drug for erectile dysfunction

7.4.1

Tadalafil 5mg Once daily

Remain as NOT APPROVED for Benign Prostatic Hyperplasia in the absence of erectile dysfunction until NICE or NHSE guidance is updated. Clarify on the formulary that tadalafil 5mg once daily tablets are approved if patient has erectile dysfunction alone OR erectile dysfunction and BPH.

3.1.2

Ipratropium nebules

Changed from RED to AMBER Specialist Initiation

4.1.1

Melatonin

Clarified that current formulary status of melatonin (neurology use) includes in Parkinson’s disease on the advice of any specialist.

6.7.2

Danzol

Removed from formulary as discontinued

3.1.2

Tiotropium

Annotate formulary to say Tiotropium in COPD should only be used for existing patients.

3.2.3

Trimbow® Nexthaler

Added as a GREEN drug for COPD

13.6.2

Spironolactone for acne

Added as a RED drug

6.1.1.1

Insulin aspart (biosimilar) Trurapi®

Added as GREEN drug

3.4.3

Adrenaline auto-injectors: reminder for prescribers to support safe and effective use

Added link to MHRA Drug Safety Update

14.4

Yellow fever vaccine (Stamaril): new pre-vaccination checklist

Added link to MHRA Drug Safety Update

4

Chloral hydrate, cloral betaine (Welldorm): restriction of paediatric indication

Added link to MHRA Drug Safety Update

1+10

Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies

Added link to MHRA Drug Safety Update

4

 

Added link to NICE NG209

2

 

Added link to NICE NG208

5

 

Added link to NICE NG191

5

 

Added link to NICE NG188

9.8.2

Givosiran

Added as a RED drug and added link to NICE HST16

8.1.5

Nintedanib

Added link to NICE TA747

8.2.4

Nivolumab

Added link to NICE TA746

8.1.5

NBTXR-3

Added as a NOT APPROVED drug and added link to NICE TA745

10.1.3

Upadacitinib

Added link to NICE TA744

8.1.5

Crizanlizumab

Added as a RED drug and added link to NICE TA743

8.1.5

Selpercatinib

Added as a RED drug and added link to NICE TA742

8.2.4

Apalutamide

Added link to NICE TA741

8.2.4

Apalutamide

Added as a RED drug and added link to NICE TA740

8.2.4

Atezolizumab

Added link to NICE TA739

3.4.3

Berotraistat

Added as a RED drug and added link to NICE TA738

8.1.5

Pembrolizumab

Added link to NICE TA737

8.2.4

Nivolumab

Added link to NICE TA736

10.1.3

Tofacitinib

Added as a RED drug for this indication and added link to NICE TA735

13.5.3

Secukinumab

Added as a RED drug for this indication and added link to NICE TA734

5.3.4

Baloxavir marboxil

Added as a NOT APPROVED drug and added link to NICE TA732

2.12

Inclisiran

Removed sentence re do not prescribe as awaiting guideline

 

Changes to Formulary as of 15th November 2021:

BNF Category Number

Product/indication

Detail of change

 

All Black Triangle Drugs

Checked that Black Triangle Status correct.

8.1.5

Chlormethine gel

Added as a RED drug and added link to NICE TA720

8.3.4.2

Abiraterone

Added as a NOT APPROVED drug for this indication and added link to NICE TA721

8.1.5

Pemigatinib

Added as a RED drug and added link to NICE TA722

8.2.4

Nivolumab

Added as a NOT APPROVED drug for this indication and added link to NICE TA724

8.1.5

Abemaciclib

Added link to NICE TA725

8.1.5

Daratumumab

Added as a NOT APPROVED drug for this indication and added link to NICE TA726

8.1.5

Isatuximab

Added as a NOT APPROVED drug for this indication and added link to NICE TA727

8.1.5

Midostaurin

Added link to NICE TA728

9.4.1

Sapropterin

Added link to NICE TA729

8.1.5

Avapritinib

Added as a NOT APPROVED drug for this indication and added link to NICE TA730

2.5.5

Vericiguat

Added as a NOT APPROVED drug and added link to NICE TA731

13.4

Topical corticosteroids: information on the risk of topical steroid withdrawal reactions

Added link to MHRA Drug Safety Update

4.10.3

Buprenorphine prolonged release injection

Added as a RED drug and added link to NTAG recommendation

4.2.1.2

Lurasidone

Changed from NOT APPROVED to AMBER SI drug for schizophrenia only and added link to NTAG recommendation

7.4.5

Tadalafil 5mg Once daily

Added link to updated NTAG recommendation

7.4.5

Tadalafil 5mg Once daily

Changed from NOT APPROVED to AMBER SI drug for erectile dysfunction

4.7.1

Nabilone

Deleted from formulary as not in current pain guidelines

5.1.2

Meropenem/Vaborbactam

Added as RED drug

4.6.2

Diazepam 2.5mg rectal tubes

Deleted from formulary as discontinued

4.3.4

Duloxetine 90mg and 120mg capsules

Added to formulary as NOT APPROVED

1.6.4

Cosmocol

Added for formulary as GREEN drug

13.13

BAD Specials

New chapter added for BAD specials

 

Changes to Formulary as of 1st November 2021:

BNF Category Number

Product/indication

Detail of change

2.12

Inclisiran

Added as a GREEN drug and added link to NICE TA733